pentoxifylline has been researched along with Alloxan Diabetes in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake." | 5.43 | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. ( Chang, ML; Chao, J; Cheng, HY; Liao, JW; Pao, LH; Peng, WH; Ye, JH, 2016) |
| " Its high solubility and rapid metabolism results in poor bioavailability and short half-life, limiting its clinical utility." | 1.51 | Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus. ( Chitkara, D; Italiya, KS; Mahato, RI; Mazumdar, S; Mittal, A; Sharma, S, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake." | 1.43 | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. ( Chang, ML; Chao, J; Cheng, HY; Liao, JW; Pao, LH; Peng, WH; Ye, JH, 2016) |
| " Adult male Wistar albino rats were randomly divided into three groups: normal control (the N group), diabetic nephropathy (the DN group), and diabetic nephropathy treated with pentoxifylline at the dosage of 20 mg x kg(-1) x d(-1), intraperitoneally (the group DNP)." | 1.32 | The effects of pentoxifylline on diabetic renal changes in streptozotocin-induced diabetes mellitus. ( Canoz, O; Dusunsel, R; Gunduz, Z; Per, H; Poyrazoglu, MH; Saraymen, R; Tez, C, 2004) |
| "Flurbiprofen co-treatment markedly attenuated these actions of pentoxifylline on nerve conduction and blood flow whereas NG-nitro-L-arginine was without effect." | 1.31 | Pentoxifylline effects on nerve conduction velocity and blood flow in diabetic rats. ( Cameron, NE; Cotter, MA; Flint, H, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 14 (41.18) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Degen, AS | 1 |
| Krynytska, IY | 1 |
| Kamyshnyi, AM | 1 |
| Şekeroğlu, MR | 1 |
| Huyut, Z | 1 |
| Çokluk, E | 1 |
| Özbek, H | 1 |
| Alp, HH | 1 |
| Mehanna, OM | 1 |
| El Askary, A | 1 |
| Al-Shehri, S | 1 |
| El-Esawy, B | 1 |
| Arcaro, CA | 1 |
| Assis, RP | 1 |
| Zanon, NM | 2 |
| Paula-Gomes, S | 1 |
| Navegantes, LCC | 1 |
| Kettelhut, IC | 1 |
| Brunetti, IL | 1 |
| Baviera, AM | 2 |
| Italiya, KS | 1 |
| Mazumdar, S | 1 |
| Sharma, S | 1 |
| Chitkara, D | 1 |
| Mahato, RI | 1 |
| Mittal, A | 1 |
| Kapoor, S | 1 |
| Sun, HK | 2 |
| Han, SY | 3 |
| Zhiliuk, VI | 1 |
| Mamchur, VI | 1 |
| Pavlov, SV | 1 |
| An, ZM | 1 |
| Dong, XG | 1 |
| Guo, Y | 1 |
| Zhou, JL | 1 |
| Qin, T | 1 |
| Shirakami, Y | 1 |
| Shimizu, M | 1 |
| Kubota, M | 1 |
| Ohno, T | 1 |
| Kochi, T | 1 |
| Nakamura, N | 1 |
| Sumi, T | 1 |
| Tanaka, T | 1 |
| Moriwaki, H | 1 |
| Seishima, M | 1 |
| Sönmez, MF | 2 |
| Kılıç, E | 1 |
| Karabulut, D | 1 |
| Çilenk, K | 1 |
| Deligönül, E | 1 |
| Dündar, M | 2 |
| Feyli, SA | 1 |
| Ghanbari, A | 1 |
| Keshtmand, Z | 1 |
| Ye, JH | 1 |
| Chao, J | 1 |
| Chang, ML | 1 |
| Peng, WH | 1 |
| Cheng, HY | 1 |
| Liao, JW | 1 |
| Pao, LH | 1 |
| Satar, B | 1 |
| Yildiz, O | 1 |
| Karatas, E | 1 |
| Boydag, S | 1 |
| Akkaya, A | 1 |
| Isken, T | 1 |
| Serdaroglu, I | 1 |
| Ozgentas, E | 1 |
| Han, KH | 2 |
| Kim, HS | 2 |
| Kang, YS | 1 |
| Cha, DR | 1 |
| Baraka, AM | 1 |
| Guemei, A | 1 |
| Gawad, HA | 1 |
| Kang, SW | 1 |
| Lee, YM | 1 |
| Ahn, SH | 1 |
| Babaei, S | 1 |
| Bayat, M | 2 |
| Nouruzian, M | 1 |
| Yang, Z | 2 |
| Chen, M | 2 |
| Fialkow, LB | 1 |
| Ellett, JD | 2 |
| Wu, R | 1 |
| Nadler, JL | 3 |
| Striffler, JS | 1 |
| Gunduz, Z | 1 |
| Canoz, O | 1 |
| Per, H | 1 |
| Dusunsel, R | 1 |
| Poyrazoglu, MH | 1 |
| Tez, C | 1 |
| Saraymen, R | 1 |
| Carter, JD | 1 |
| Smith, KM | 1 |
| Dávila-Esqueda, ME | 1 |
| Vertiz-Hernández, AA | 1 |
| Martínez-Morales, F | 1 |
| Carvalho Navegantes, LC | 1 |
| Migliorini, RH | 1 |
| do Carmo Kettelhut, I | 1 |
| Colen, LB | 1 |
| Stevenson, A | 1 |
| Sidorov, V | 1 |
| Potparic, Z | 1 |
| Pacelli, E | 1 |
| Searles, J | 1 |
| Lee, S | 1 |
| Li, L | 1 |
| Bonnardel-Phu, E | 1 |
| Vicaut, E | 1 |
| Juang, JH | 1 |
| Kuo, CH | 1 |
| Hsu, BR | 1 |
| Stosić-Grujicić, S | 1 |
| Maksimović, D | 2 |
| Badovinac, V | 1 |
| Samardzić, T | 1 |
| Trajković, V | 1 |
| Lukić, M | 1 |
| Mostarica Stojković, M | 1 |
| Flint, H | 1 |
| Cotter, MA | 1 |
| Cameron, NE | 1 |
| Stosić-Grujicić, SD | 1 |
| Maksimović, DD | 1 |
| Stojković, MB | 1 |
| Lukić, ML | 2 |
| Mensah-Brown, EP | 1 |
| Stosic Grujicic, S | 1 |
| Jasima, A | 1 |
| Shahin, A | 1 |
34 other studies available for pentoxifylline and Alloxan Diabetes
| Article | Year |
|---|---|
Changes in the transcriptional activity of the entero-insular axis genes in streptozotocin-induced diabetes and after the administration of TNF-α non-selective blockers.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Gene Expression; Glucagon-Like Pep | 2020 |
The susceptibility to autoxidation of erythrocytes in diabetic mice: Effects of melatonin and pentoxifylline.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Erythrocytes; Free Radical S | 2017 |
Effect of phosphodiesterase inhibitors on renal functions and oxidant/antioxidant parameters in streptozocin-induced diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hyperglycemia; Hypog | 2018 |
Involvement of cAMP/EPAC/Akt signaling in the antiproteolytic effects of pentoxifylline on skeletal muscles of diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Cyclic AMP; Diabetes Mellitus, Experimental; Drug Evaluation, P | 2018 |
Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Diabetes Mellitus, Experimental; Inflam | 2019 |
The renoprotective effects of pentoxifylline: beyond its role in diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoxia; Kidney Tubules; Male; Pen | 2013 |
In reply.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoxia; Kidney Tubules; Male; Pen | 2013 |
[Role of functional state of neuronal mitochondria of cerebral cortex in mechanisms of nootropic activity of neuroprotectors in rats with alloxan hyperglycemia].
Topics: Alloxan; Amnesia; Animals; Avoidance Learning; Cerebral Cortex; Cognition; Cytidine Diphosphate Chol | 2015 |
Effects and clinical significance of pentoxifylline on the oxidative stress of rats with diabetic nephropathy.
Topics: Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regula | 2015 |
Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis.
Topics: Animals; Diabetes Mellitus, Experimental; Inflammation; Lipogenesis; Liver Neoplasms, Experimental; | 2016 |
Nitric oxide synthase in diabetic rat testicular tissue and the effects of pentoxifylline therapy.
Topics: Animals; Apoptosis; Biopsy; Diabetes Mellitus, Experimental; Enzyme-Linked Immunosorbent Assay; Isoe | 2016 |
Ameliorative effects of pentoxifylline on NOS induced by diabetes in rat kidney.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Male; Nitric Oxide Synthas | 2016 |
Therapeutic effect of pentoxifylline on reproductive parameters in diabetic male mice.
Topics: Animals; Apoptosis; Blood Glucose; Diabetes Mellitus, Experimental; Epididymis; Male; Mice; Pentoxif | 2017 |
Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dyslipidemias; Fa | 2016 |
Pentoxifylline response in alloxan-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Evoked Potentials, Auditory, Brain Stem; Hearing Loss, Sen | 2008 |
The effects of the pentoxifylline on survival of the skin flaps in streptozotocin-diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Female; Graft Survival; Pentoxifylline; Rats; Rats, Wistar | 2009 |
Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Chemokin | 2010 |
Role of modulation of vascular endothelial growth factor and tumor necrosis factor-alpha in gastric ulcer healing in diabetic rats.
Topics: Acetic Acid; Animals; Anticholesteremic Agents; Diabetes Mellitus, Experimental; Free Radical Scaven | 2010 |
Effect of phosphodiesterase inhibitor on diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoxia; Kidney Tubules; Male; Pen | 2012 |
Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney.
Topics: Animals; Cell Line; Cobalt; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, | 2012 |
Pentoxifylline improves cutaneous wound healing in streptozotocin-induced diabetic rats.
Topics: Animals; Biomechanical Phenomena; Blood Vessels; Cell Count; Diabetes Mellitus, Experimental; Epithe | 2013 |
The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Differentiation; Diabetes Mellitus, Expe | 2003 |
Lisofylline, a novel anti-inflammatory agent, enhances glucose-stimulated insulin secretion in vivo and in vitro: studies in prediabetic and normal rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Diabetes Mellitus, Experimental; Ea | 2004 |
The effects of pentoxifylline on diabetic renal changes in streptozotocin-induced diabetes mellitus.
Topics: Animals; Biopsy, Needle; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, An | 2004 |
Inflammation blockade improves pancreatic islet function.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Cytokines; Diabetes Mellitus, Exp | 2004 |
Comparative analysis of the renoprotective effects of pentoxifylline and vitamin E on streptozotocin-induced diabetes mellitus.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypertrophy; Kidney; | 2005 |
Pentoxifylline inhibits Ca2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium-Binding Proteins; Calpain; Cyclic AMP; Diabetes Me | 2007 |
Microvascular anastomotic thrombosis in experimental diabetes mellitus.
Topics: Anastomosis, Surgical; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Angiopathie | 1997 |
[Role of oxidative stress in permeability changes observed in the microcirculation of diabetic rats in vivo].
Topics: Animals; Capillary Permeability; Catalase; Diabetes Mellitus, Experimental; Diabetic Angiopathies; D | 2000 |
Beneficial effects of pentoxiphylline on islet transplantation.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Insulin; Islets of Langerhans; | 2000 |
Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Interferon-gamma; Mi | 2001 |
Pentoxifylline effects on nerve conduction velocity and blood flow in diabetic rats.
Topics: Animals; Blood Glucose; Cyclooxygenase Inhibitors; Diabetes Mellitus, Experimental; Flurbiprofen; Ma | 2000 |
Pentoxifylline prevents autoimmune mediated inflammation in low dose streptozotocin induced diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Islets of Langer | 2001 |
Downregulation of apoptosis in the target tissue prevents low-dose streptozotocin-induced autoimmune diabetes.
Topics: Animals; Apoptosis; Blood Glucose; Cell Movement; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2002 |